Cory Kasimov
Stock Analyst at Evercore ISI Group
(4.28)
# 421
Out of 4,876 analysts
77
Total ratings
57.41%
Success rate
14.97%
Average return
Main Sectors:
Stocks Rated by Cory Kasimov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XENE Xenon Pharmaceuticals | Initiates: Outperform | $55 | $32.40 | +69.75% | 1 | May 14, 2025 | |
| MRNA Moderna | Maintains: In-Line | $50 → $32 | $27.16 | +17.82% | 6 | May 2, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $190 → $185 | $125.42 | +47.50% | 2 | Apr 24, 2025 | |
| SMMT Summit Therapeutics | Initiates: Outperform | $30 | $20.60 | +45.63% | 1 | Mar 12, 2025 | |
| SWTX SpringWorks Therapeutics | Maintains: Outperform | $60 → $65 | $46.98 | +38.36% | 2 | Feb 12, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $45 → $50 | $44.86 | +11.46% | 3 | Dec 23, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Outperform | $45 → $50 | $13.17 | +279.65% | 2 | Dec 17, 2024 | |
| BNTX BioNTech SE | Upgrades: Outperform | $110 → $125 | $106.72 | +17.13% | 4 | Nov 19, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Outperform | $115 → $105 | $55.17 | +90.32% | 12 | Oct 30, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $1,250 → $1,175 | $521.00 | +125.53% | 5 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $85 | $65.35 | +30.07% | 1 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $84 → $88 | $36.52 | +140.96% | 6 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $324 → $276 | $126.08 | +118.91% | 4 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $2.81 | +1,145.55% | 1 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $232 | $277.13 | -16.28% | 5 | Jul 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $68.37 | - | 5 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $110.67 | - | 5 | May 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $21 | $28.81 | -27.11% | 4 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $83 → $23 | $3.33 | +590.69% | 6 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $310 → $250 | $9.91 | +2,422.70% | 1 | Feb 14, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $15 → $10 | $0.82 | +1,118.18% | 1 | Feb 14, 2018 |
Xenon Pharmaceuticals
May 14, 2025
Initiates: Outperform
Price Target: $55
Current: $32.40
Upside: +69.75%
Moderna
May 2, 2025
Maintains: In-Line
Price Target: $50 → $32
Current: $27.16
Upside: +17.82%
Neurocrine Biosciences
Apr 24, 2025
Maintains: Outperform
Price Target: $190 → $185
Current: $125.42
Upside: +47.50%
Summit Therapeutics
Mar 12, 2025
Initiates: Outperform
Price Target: $30
Current: $20.60
Upside: +45.63%
SpringWorks Therapeutics
Feb 12, 2025
Maintains: Outperform
Price Target: $60 → $65
Current: $46.98
Upside: +38.36%
BridgeBio Pharma
Dec 23, 2024
Maintains: Outperform
Price Target: $45 → $50
Current: $44.86
Upside: +11.46%
Edgewise Therapeutics
Dec 17, 2024
Maintains: Outperform
Price Target: $45 → $50
Current: $13.17
Upside: +279.65%
BioNTech SE
Nov 19, 2024
Upgrades: Outperform
Price Target: $110 → $125
Current: $106.72
Upside: +17.13%
BioMarin Pharmaceutical
Oct 30, 2024
Maintains: Outperform
Price Target: $115 → $105
Current: $55.17
Upside: +90.32%
Regeneron Pharmaceuticals
Oct 24, 2024
Maintains: Outperform
Price Target: $1,250 → $1,175
Current: $521.00
Upside: +125.53%
May 14, 2024
Initiates: Outperform
Price Target: $85
Current: $65.35
Upside: +30.07%
Feb 27, 2024
Maintains: Overweight
Price Target: $84 → $88
Current: $36.52
Upside: +140.96%
Dec 21, 2021
Maintains: Neutral
Price Target: $324 → $276
Current: $126.08
Upside: +118.91%
Mar 1, 2021
Initiates: Neutral
Price Target: $35
Current: $2.81
Upside: +1,145.55%
Jul 29, 2020
Maintains: Neutral
Price Target: $225 → $232
Current: $277.13
Upside: -16.28%
May 6, 2020
Downgrades: Neutral
Price Target: n/a
Current: $68.37
Upside: -
May 1, 2020
Downgrades: Neutral
Price Target: n/a
Current: $110.67
Upside: -
Feb 14, 2020
Downgrades: Neutral
Price Target: $25 → $21
Current: $28.81
Upside: -27.11%
Nov 2, 2018
Maintains: Underweight
Price Target: $83 → $23
Current: $3.33
Upside: +590.69%
Feb 14, 2018
Maintains: Neutral
Price Target: $310 → $250
Current: $9.91
Upside: +2,422.70%
Feb 14, 2018
Maintains: Underweight
Price Target: $15 → $10
Current: $0.82
Upside: +1,118.18%